CEO Heather Turner was paid $11,884,985 in fiscal year 2025, ↑ up 148.0% from fiscal year 2024 (SEC filing 0001193125-26-173679 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$11,884,985 ↑ Heather Turner total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
LBRX's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Heather Turner | $568,750 | $321,406 | $0 | $10,865,221 | $0 | $0 | $129,608 | $11,884,985 |
| Chief Executive Officer | ||||||||
| Gad Soffer | 402,292 | 194,150 | — | 3,200,445 | — | — | 11,750 | 3,808,637 |
| Chief Operating and Business Officer | ||||||||
| Anna Eramo | 414,063 | 182,188 | 0 | 1,760,006 | 0 | 0 | 20,682 | 2,376,939 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Heather Turner | $11,884,985 | $4,792,690 | — | ↑ +7,092,295 |
| Gad Soffer | 3,808,637 | — | — | — |
| Anna Eramo | 2,376,939 | 891,050 | — | ↑ +1,485,889 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read LB Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper LBRX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Heather Turner | Option | 128,120 | 15 | — |
| Heather Turner | Option | 5,730 | 15 | — |
| Heather Turner | Option | 971,828 | 15 | — |
| Gad Soffer | Option | 26,893 | 15 | — |
| Anna Eramo | Option | 11,206 | 15 | — |
| Gad Soffer | Option | 229,860 | 15 | — |
| Anna Eramo | Option | 3,923 | 15 | — |
| Anna Eramo | Option | 155,812 | 15 | — |
The Compensation Committee seeks to align executive compensation with the Company's long-term strategic goals and stockholder value creation, ensuring retention and incentive alignment through equity and cash compensation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-03 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | LB Pharmaceuticals | 2025 | Heather Turner | $568,750 | $0 | $10,865,221 | $0 | $11,884,985 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Heather Turner | DEF 14A | 2026-04-23 | 0001193125-26-173679 | Section “Executive Compensation”. As printed: 11,884,985. Filing ↗machine: r2 · c22 · span 204304–204314 |
| 2 | Section 01, Gad Soffer | DEF 14A | 2026-04-23 | 0001193125-26-173679 | Section “Executive Compensation”. As printed: 3,808,637. Filing ↗ |
| 3 | Section 01, Anna Eramo | DEF 14A | 2026-04-23 | 0001193125-26-173679 | Section “Executive Compensation”. As printed: 2,376,939. Filing ↗machine: r6 · c22 · span 211444–211453 |
| 4 | Section 07, pay ratio | 10-K | 2026-03-26 | 0001193125-26-126368 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Section 06, 2026 vote | Form 8-K | 2026-06-09 | 0001193125-26-263724 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 6 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 7 | LB Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173679 | CEO total compensation as printed in LB Pharmaceuticals's own proxy. As printed: 11,884,985. Filing ↗machine: r2 · c22 · span 204304–204314 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.